RNA — Avidity Biosciences Income Statement
0.000.00%
Last trade - 00:00- $3.71bn
- $2.21bn
- $10.90m
- 49
- 11
- 39
- 24
Annual income statement for Avidity Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.79 | 9.33 | 9.22 | 9.56 | 10.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 51.1 | 127 | 188 | 245 | 390 |
| Operating Profit | -44.3 | -118 | -179 | -236 | -379 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -44.4 | -118 | -174 | -212 | -322 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44.4 | -118 | -174 | -212 | -322 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44.4 | -118 | -174 | -212 | -322 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44.4 | -118 | -174 | -212 | -322 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.18 | -2.85 | -3.34 | -2.91 | -2.89 |